

Adamas Pharmaceuticals develops controlled release combination therapeutics for infectious diseases and central nervous system disorders. Among its major competitors, Adamas Pharmaceuticals is ranked in 8th place for NPS while Alexza Pharmaceuticals is 1st, and Amphastar Pharmaceuticals is 2nd.Their current market cap is $167.42M
Adamas Pharmaceuticals has an overall Product Quality score of 5 out of 5 stars rated by its users and customers.
Sign Up to unlock Adamas Pharmaceuticals' overall Product Quality score rated by its users and customers.
Adamas Pharmaceuticals’s product quality score is a 5 out of 5 as rated by its users and customers.
Compared to its competitors, Adamas Pharmaceuticals's Product Quality score is rated right above Pfizer.
| COMPANY | Product Quality Score | |
|---|---|---|
![]() | Adamas Pharmaceuticals | 5/5 |
![]() | Pfizer | 3.2/5 |
![]() | Mylan | 2.5/5 |
![]() | Alexza Pharmaceuticals | 2.5/5 |
![]() | Amphastar Pharmaceuticals | N/A |
![]() | Forest Laboratories | N/A |
Adamas Pharmaceuticals has a value for money and ROI score of 4 out of 5 stars rated by its users and customers.
Sign Up to unlock Adamas Pharmaceuticals' overall ROI score rated by its users and customers.
Compared to its competitors, Adamas Pharmaceuticals's ROI score is rated right above Pfizer.
| COMPANY | Pricing Score | |
|---|---|---|
![]() | Adamas Pharmaceuticals | 4/5 |
![]() | Pfizer | 3.1/5 |
![]() | Mylan | 3/5 |
![]() | Alexza Pharmaceuticals | N/A |
![]() | Amphastar Pharmaceuticals | N/A |
![]() | Forest Laboratories | N/A |